Show simple item record

dc.contributor.authorPalacios, Eduardospa
dc.contributor.authorPradilla, Oscarspa 00:00:00
dc.publisherSociedad de Cirugía de Bogotá, Hospital de San José y Fundación Universitaria de Ciencias de la Saludspa
dc.rightsFundación Universitaria de Ciencias de la Salud FUCS - 0spa
dc.subjectácido valproicospa
dc.subjectvalproic acideng
dc.titleAnticonvulsionantes: Profilaxis de migrañaspa
dc.typeArtículo de revistaspa
dc.typeJournal articleeng 00:00:00
dc.relation.referencesCutrer FM. Antiepileptic drugs: how they work in headache. Headache. 2001 Nov-Dec;41 Suppl
dc.relation.referencesPost RM, Silberstein SD. Shared mechanisms in affective illness, epilepsy, and migraine. Neurology. 1994 Oct;44(10 Suppl 7)
dc.relation.referencesSorensen KV. Valproate: a new drug in migraine prophylaxis. Acta Neurol Scand. 1988 Oct;78(4)
dc.relation.referencesCalabresi P, Galletti F, Rossi C, Sarchielli P, Cupini LM. Antiepileptic drugs in migraine: from clinical aspects to cellular mechanisms. Trends Pharmacol Sci. 2007 Apr;28(4)
dc.relation.referencesRamadan NM. Current trends in migraine prophylaxis. Headache. 2007 Apr;47 Suppl
dc.relation.referencesGoadsby PJ, Lipton RB, Ferrari MD. Migraine--current understanding and treatment. N Engl J Med. 2002 Jan 24;346(4)
dc.relation.referencesRogawski MA, Lóscher W. The neurobiology of antiepileptic drugs for the treatment of nonepileptic conditions. Nat Med. 2004 Jul;10(7)
dc.relation.referencesKelly KM. Gabapentin. Antiepileptic mechanism of action. Neuropsychobiology. 1998 Oct;38(3):
dc.relation.referencesMorris GL. Gabapentin. Epilepsia. 1999;40 Suppl 5:S63-
dc.relation.referencesGoadsby PJ. Can we develop neurally acting drugs for the treatment of migraine? Nat Rev Drug Discov. 2005 Sep;4(9)
dc.relation.referencesMagnus L. Nonepileptic uses of gabapentin. Epilepsia. 1999;40 Suppl
dc.relation.referencesGlauser TA.Topiramate.Epilepsia. 1999;40 Suppl 5:S71-
dc.relation.referencesSilberstein SD. Practice parameter: evidence-based guidefines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2000 Sep 26;55(6)
dc.relation.referencesLuo ZD, Chaplan SR, Higuera ES, Sorkin LS, Stauderman KA, Williams ME, Yaksh TL. Upregulation of dorsal root ganglion (alpha)2(delta) calcium channel subunit and its correlation with allodynia in spinal nerve-injured rats. J Neurosci. 2001 Mar 15;21(6)
dc.relation.referencesBayer K, Ahmadi S, Zeilhofer HU. Gabapentin may inhibit synaptic transmission in the mouse spinal cord dorsal hom through a preferential block of P/Q-type Ca2+ channels. Neuropharmacology. 2004 Apr;46(5)
dc.relation.referencesEvans RW, Loder E, Biondi DM. When can successful migraine prophylaxis be discontinued? Headache. 2004 Nov-Dec;44(10)
dc.relation.referencesRapoport AM, Bigal ME. Migraine preventive therapy: current and emerging treatment options. Neurol Sci. 2005 May;26 Suppl
dc.relation.referencesChronicle E, Mulleners W.Anticonvulsant drugs for migraine prophylaxis. Cochrane Database Syst Rev. 2004;(3)
dc.relation.referencesCutrer FM, Limmroth V, Moskowitz MA. Possible mechanisms of valproate in migraine prophylaxis. Cephalalgia. 1997 Apr;17(2)
dc.relation.referencesGraff-Radford SB. Migraine Prophylaxis. Clin Fam Pract. Sep 2005;7(3)
dc.relation.referencesKinze S, Clauss M, Reuter U, Wolf T, Dreier JP, Einháupl KM, Arnold G. Valproic acid is effective in migraine prophylaxis at low serum levels: a prospective open-label study. Headache. 2001 Sep;41(8)
dc.relation.referencesFrediani F. Anticonvulsant drugs in primary headaches prophylaxis. Neurol Sci. 2004 Oct;25 Suppl
dc.relation.referencesTaylor K, Goldstein J. High-dose versus low-dose valproic acid as a prophylactic medication. Headache. 1996 Sep;36(8)
dc.relation.referencesMembers of the task force:, Evers S, Afra J, Frese A, Goadsby PJ, Linde M, May A, Sándor PS. EFNS guideline on the drug treatment of migraine - report of an EFNS task force. Eur J Neurol. 2006 Jun;13(6)
dc.relation.referencesJensen R, Brinck T, Olesen J. Sodium valproate has a prophylactic effect in migraine without aura: a triple-blind, placebo-controlled crossover study. Neurology. 1994 Apr;44(4):
dc.relation.referencesRothrock JF, Mendizabal JE. An analysis of the "carryover effect" following successful short-term treatment of transformed migraine with divalproex sodium. Headache. 2000 Jan;40(1)
dc.relation.referencesSilberstein SD, Goadsby PJ. Migraine: preventive treatment. Cephalalgia. 2002 S ep;22(7)
dc.relation.referencesD'Amico D. Antiepileptic drugs in the prophylaxis of migraine, chronic headache forms and cluster headache: a review of their efficacy and tolerability. Neurol Sci. 2007 May;28 Suppl
dc.relation.referencesHering R, Kuritzky A. Sodium valproate in the prophylactic treatment of migraine: a double-blind study versus placebo. Cephalalgia. 1992 Apr;12(2)
dc.relation.referencesShaygannejad V, Janghorbani M, Ghorbani A, Ashtary F, Zakizade N, Nasr V. Comparison of the effect of to- piramate and sodium valporate in migraine prevention: a randomized blinded crossover study. Headache. 2006 Apr;46(4)
dc.relation.referencesMathew NT, Saper JR, Silberstein SD, Rankin L, Markley HG, Solomon S, Rapoport AM, Silber CJ, Deaton RL. Migraine prophylaxis with divalproex. Arch Neurol. 1995 Mar;52(3)
dc.relation.referencesSilberstein SD. Divalproex sodium in headache: literature review and clinical guidelines. Headache. 1996 Oct;36(9)
dc.relation.referencesPennell PB. Pregnancy in the woman with epilepsy: maternal and fetal outcomes. Semin Neurol. 2002 Sep;22(3)
dc.relation.referencesStorey JR, Calder CS, Hart DE, Potter DL. Topiramate in migraine prevention: a double-blind, placebo-controlled study. Headache. 2001 Nov-Dec;41(10)
dc.relation.referencesSilberstein SD Topiramate in migraine prevention: evidence-based medicine from clinical trials. Neurol Sci. 2004 Oct;25 Suppl
dc.relation.referencesSilberstein SD. Topiramate in migraine prevention. Headache. 2005 Apr;45 Suppl
dc.relation.referencesPeres MF, Mercante JP, Tanuri FC, Nunes M, Zukerman E. Chronic migraine prevention with topiramate. J Headache Pain. 2006 Sep;7(4)
dc.relation.referencesGupta P, Singh S, Goyal V, Shukla G, Behari M. Low-dose topiramate versus lamotrigine in migraine prophylaxis (the Lotolamp study). Headache. 2007 Mar;47(3)
dc.relation.referencesRichard D, Ferland J, Lalonde J, Samson P, Deshaies Y. Influenceoftopiramate in the regulation of energy balance. Nutrition. 2000 Oct;16(10)
dc.relation.referencesGreenwood RS. Adverse effects of antiepileptic drugs. Epilepsia. 2000;41 Suppl
dc.relation.referencesCissoko H, Jonville-Béra AP, Autret-Leca E. [New antiepileptic drugs in pregnancy: outcome of 12 exponed pregnancies] Therapie. 2002 Jul-Aug;57(4)
dc.relation.referencesVila Cerén C, Demestre Guasch X, Raspall Torrent F, Elizari Saco MJ, Sala Castellví P, Martínez Nadal S. [Topiramate and pregnancy. Neonate with bone anomalies]An Pediatr (Barc). 2005 Oct;63(4)
dc.relation.referencesPetroff 0A, Rothman DL, Behar KL, Lamoureux D, Mattson RH. The effect of gabapentin on brain gammaaminobutyric acid in patients with epilepsy.Ann Neurol. 1996 Jan;39(1)
dc.relation.referencesMathew NT, Rapoport A, Saper J, Magnus L, Klapper J, Ramadan N, Stacey B, Tepper S. Efficacy of gabapentin in migraine prophylaxis. Headache. 2001 Feb;41(2)
dc.relation.referencesDi Trapani G, Mei D, Marra C, Mazza S, Capuano A. Gabapentin in the prophylaxis of migraine: a double-blind randomized placebo-controlled study. Clin Ter. 2000 May-Jun;151(3)
dc.relation.referencesBuchanan TM, Ramadan NM. Prophylactic pharmacotherapy for migraine headaches. Semin Neurol. 2006 Apr;26(2)
dc.relation.referencesKrymchantowski AV, Bigal ME, Moreira PF.New and emerging prophylactic agents for migraine. CNS Drugs. 2002;16(9)
dc.relation.referencesSilberstein SD. Preventive treatment of migraine Trends Pharmacol Sci. 2006 Aug;27(8)
dc.relation.citationeditionNúm. 3 , Año 2008 : Julio – Septiembrespa
dc.relation.ispartofjournalRevista Repertorio de Medicina y Cirugíaspa
dc.title.translatedAnticonvulsants: Migraine prophylaxiseng

Files in this item

Repert. Med. Cir.-505.pdf5.033Mbapplication/pdfView/Open

This item appears in the following Collection(s)

Show simple item record

Fundación Universitaria de Ciencias de la Salud FUCS - 0
Except where otherwise noted, this item's license is described as Fundación Universitaria de Ciencias de la Salud FUCS - 0